RenovoRx, Inc.
NASDAQ:RNXTBiotechnology
-$0.01 today
- Market cap
- $54.04M
- Beta
- 0.99
- P/E (TTM)
- -3.4
- EPS (TTM)
- -$0.32
Volume 0.84M
Average 0.29M
RNXT Cash & Equivalents
Cash on hand and highly liquid investments that can be converted to cash almost immediately.
RenovoRx, Inc.NASDAQ: RNXT
Cash & Equivalents · Q1 FY2026 · quarter ended Mar 2026
Cash & equivalents falls 15.2% from a year ago
Cash & equivalents stood at $12.36M at the end of Q1 FY2026, down 15.2% from a year earlier and up 76.0% from the prior quarter. Over 3 fiscal years it compounded at +17.0% a year.
Context
- Cash & equivalents amounted to 88.5% of total assets at the end of Q1 FY2026, down 2.5 pp from a year earlier.
- Cash & equivalents increased in 1 of the last 3 fiscal years.
What to watch
Whether cash & equivalents keeps falling in the next quarterly balance sheet after a -15.2% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Cash & Equivalents history
USD · from the balance sheet
- Latest · FY2025
- 7.02M USD
- Year-over-year change
- -1.8%
- 4-year CAGR
- -17.5%
| Period | Period end | Cash & Equivalents | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 7.02M | -1.8% |
| FY2024 | 2024-12-31 | 7.15M | +509.9% |
| FY2023 | 2023-12-31 | 1.17M | -73.3% |
| FY2022 | 2022-12-31 | 4.39M | -71.1% |
| FY2021 | 2021-12-31 | 15.19M | — |
Cash & Equivalents vs competitors
How RNXT compares with its peers on the latest reported figures
- RNXT's Mar 2026 cash & equivalents of $12.36M is the 3rd highest of the 6 companies compared; the peer median is $9.08M.
- Its year-over-year change of -15.2% is the 4th highest of 6, against a peer median of +216.8%.
- Cash & equivalents amounts to 88.5% of total assets for RNXT, versus a peer median of 68.1%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $34.41M | +216.8% | +824.7% | 97.4% | |
| Mar 2026 | $14.22M | -36.1% | -11.7% | 87.5% | |
| Mar 2026 | $12.36M | -15.2% | +17.0% | 88.5% | |
| Mar 2026 | $9.08M | +299.7% | -9.2% | 47.4% | |
| Dec 2025 | $6.18M | +736.7% | -23.8% | 5.8% | |
| Mar 2026 | $4.92M | -22.9% | +391.7% | 68.1% | |
| Peer median (excluding RNXT) | $9.08M | +216.8% | -9.2% | 68.1% | |
Competitors are the stored peer set for RNXT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
RenovoRx, Inc.
NASDAQ:RNXT
Intrinsic Alpha fair value
Locked
Current Price
$1.12
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.